On Jan. 8 the US Food and Drug Administration (FDA) approved Savaysa (edoxaban tablets) as an anti-clotting drug in the reduction of stroke and systemic embolism risk in patients with atrial fibrillation (Afib) not caused by a heart valve problem. The drug has also been approved as a treatment for deep vein thrombosis and pulmonary embolism in patients already treated with an anti-clotting drug. Read more about previous FDA decisions regarding edoxaban.

Read the FDA’s announcement.

Keywords: Atrial Fibrillation, Embolism, Pulmonary Embolism, Pyridines, Stroke, Thiazoles, United States Food and Drug Administration, Venous Thrombosis, Factor Xa Inhibitors

< Back to Listings